27-nor-3α,7α,12α-trihydroxy-5β-cholestan-26-oic acid | 6246-77-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 27-nor-3α,7α,12α-trihydroxy-5β-cholestan-26-oic acid
• 英文别名: bishomocholic acid；3α,7α,12α-trihydroxy-27-nor-5β-cholestan-26-oic acid；3α,7α,12α-Trihydroxy-27-nor-5β-cholestan-26-saeure；Dihomocholic acid；(6R)-6-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanoic acid
• CAS: 6246-77-1
• 化学式: C₂₆H₄₄O₅
• 分子量: 436.632
• InChiKey: MLGBVVWQFBWIGT-HZAMXZRMSA-N

物化性质

• 沸点：
  602.8±55.0 °C(Predicted)
• 密度：
  1.155±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  27-nor-3α,7α,12α-trihydroxy-5β-cholestan-26-oic acid 在 chromium(VI) oxide 、 溶剂黄146 作用下， 生成 3,7,12-trioxo-27-nor-5β-cholestan-26-oic acid
  参考文献：
  名称：

  Bridgwater, Biochemical Journal, 1956, vol. 64, p. 593,597

  摘要：

  DOI：
• 作为产物：
  描述：

  (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-dimethyl-17-((R)-5-oxopentan-2-yl)hexadecahydro-1H-cyclopenta[a] phenanthrene-3,7,12-triyl triacetate 在 palladium on activated charcoal 氢氧化钾 、 氢气 作用下， 以 甲醇 、 乙酸乙酯 、 甲苯 为溶剂， 80.0 ℃ 、101.33 kPa 条件下， 反应 38.0h， 生成 27-nor-3α,7α,12α-trihydroxy-5β-cholestan-26-oic acid
  参考文献：
  名称：

  Non-stereoselective Formation of 3.ALPHA.,7.ALPHA.,12.ALPHA.,24-Tetrahydroxy-5.BETA.-cholestan- 26-oic Acid during Cholic Acid Biosynthesis.

  摘要：

  将(25RS)-、(25R)-和(25S)-3α, 7α, 12α-三羟基-5β-胆烷-26-酸（THCA，6，6a，6b）以及(24E)-3α, 7α, 12α-三羟基-5β-胆甾-24-烯-26-酸（7）与大鼠肝线粒体结合，产生了4种立体异构体（9a，9b，9c，9d）——3α, 7α, 12α, 24-四羟基-5β-胆烷-26-酸（TeHCA）。相应的27-去氢衍生物（10，11）也非选择性地转化为1:1混合物的对映体24-羟基化合物（12）。

  DOI：

  10.1248/cpb.42.1028

文献信息

• Kazuno et al., Proceedings of the Japan Academy, 1954, vol. 30, p. 987,989
  作者：Kazuno et al.

  DOI：——

  日期：——
• Iterative Probability Kinematics
  作者：Horacio Arló-Costa、Richmond H. Thomason

  DOI：10.1023/a:1012277218013

  日期：2001.10

  Following the pioneer work of Bruno De Finetti [12], conditional probability spaces (allowing for conditioning with events of measure zero) have been studied since (at least) the 1950's. Perhaps the most salient axiomatizations are Karl Popper's in [31], and Alfred Renyi's in [33]. Nonstandard probability space [34] are a well known alternative to this approach. Vann McGee proposed in [30] a result relating both approaches by showing that the standard values of infinitesimal probability functions are representable as Popper functions, and that every Popper function is representable in terms of the standard real values of some infinitesimal measure. Our main goal in this article is to study the constraints on (qualitative and probabilistic) change imposed by an extended version of McGee's result. We focus on an extension capable of allowing for iterated changes of view. Such extension, we argue, seems to be needed in almost all considered applications. Since most of the available axiomatizations stipulated (definitionally) important constraints on iterated change, we propose a non-question-begging framework, Iterative Probability Systems (IPS) and we show that every Popper function can be regarded as a Bayesian IPS. A generalized version of McGee's result is then proved and several of its consequences considered. In particular we note that our proof requires the imposition of Cumulativity, i.e. the principle that a proposition that is accepted at any stage of an iterative process of acceptance will continue to be accepted at any later stage. The plausibility and range of applicability of Cumulativity is then studied. In particular we appeal to a method for defining belief from conditional probability (first proposed in [42] and then slightly modified in [6] and [3]) in order to characterize the notion of qualitative change induced by Cumulative models of probability kinematics. The resulting cumulative notion is then compared with existing axiomatizations of belief change and probabilistic supposition. We also consider applications in the probabilistic accounts of conditionals [1] and [30].
• COMPOSITION AND USES THEREOF
  申请人：Mikov Momir

  公开号：US20090074895A1

  公开（公告）日：2009-03-19

  The present invention relates to a composition used to treat hyperglycaemia and associated conditions. In particular, the present invention relates to a composition comprising an extract from at least one plant from the genus Stevia and at least one bile salt, salt thereof or derivative thereof admixed in a form suitable for therapeutic administration.
• Composition for the Control of Cholesterol Levels
  申请人：Mikov Momir

  公开号：US20090232913A1

  公开（公告）日：2009-09-17

  The present invention relates to a composition used to control cholesterol levels. In particular, the present invention relates to a method for the treatment or prevention of disorders or diseases mediated by hyperlipidemia, said method comprising administering to a mammalian subject in need thereof an effective amount of a composition comprising an extract from at least one plant from the genus Stevia and at least one bile salt, salt thereof or derivative thereof admixed in a form suitable for therapeutic administration.
• Non-stereoselective Formation of 3.ALPHA.,7.ALPHA.,12.ALPHA.,24-Tetrahydroxy-5.BETA.-cholestan- 26-oic Acid during Cholic Acid Biosynthesis.
  作者：Noriko KOBAYASHI、Chiaki HAGIWARA、Masuo MORISAKI、Masatoshi YURI、Izumi OYA、Yoshinori FUJIMOTO

  DOI：10.1248/cpb.42.1028

  日期：——

  Incubation of (25RS)-, (25R)- and (25S)-3α, 7α, 12α-trihydroxy-5β-cholestan-26-oic acid (THCA, 6, 6a, 6b) and (24E)-3α, 7α, 12α-trihydroxy-5β-cholest-24-en-26-oic acid (7) with rat liver mitochondria gave all four stereoisomers (9a, 9b, 9c, 9d) of 3α, 7α, 12α, 24-Tetrahydroxy-5β-cholestan-26-oic acid (TeHCA). The corresponding 27-nor analogs (10, 11) were also converted non-stereoselectively to a 1 : 1 mixture of the epimeric 24-hydroxy compounds (12).

  将(25RS)-、(25R)-和(25S)-3α, 7α, 12α-三羟基-5β-胆烷-26-酸（THCA，6，6a，6b）以及(24E)-3α, 7α, 12α-三羟基-5β-胆甾-24-烯-26-酸（7）与大鼠肝线粒体结合，产生了4种立体异构体（9a，9b，9c，9d）——3α, 7α, 12α, 24-四羟基-5β-胆烷-26-酸（TeHCA）。相应的27-去氢衍生物（10，11）也非选择性地转化为1:1混合物的对映体24-羟基化合物（12）。